BioSenic S.A. (EBR:BIOS)

Market Cap	1.04M
Revenue (ttm)	2.87M
Net Income (ttm)	-7.44M
Shares Out	652.86M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,113,967
Average Volume	6,731,076
Open	0.0017
Previous Close	0.0016
Day's Range	0.0016 - 0.0017
52-Week Range	0.0012 - 0.0360
Beta	-2.85
RSI	46.75
Earnings Date	Apr 25, 2025

About BioSenic

BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company’s investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult ti...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: François Rieger
• Country: Belgium
• Stock Exchange: Euronext Brussels
• Ticker Symbol: BIOS

Financial Performance

In 2023, BioSenic's revenue was 543,000, an increase of 104.14% compared to the previous year's 266,000. Losses were -28.78 million, 843.9% more than in 2022.